glp-1 and blood clots meds might reduce clot risk in diabetes patients A recent study suggests that
Description
mTOR: mammalian target of rapamycin
Int J Nanomed, 2025

M., Reimann F., and Trapp S., Distribution and Characterisation of GlucagonLike Peptide1 Receptor Expressing Cells in the Mouse Brain, Molecular Metabolism 4, no

Consequently, the potential for this class of drugs is enormous and may be a paradigm shift not only for the management of obesity but also for several other conditions

What about combining both medications
